SUBSCRIBE
SUBSCRIBE

MAIA Biotechnology

IN THE PRESS
Drug Development
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
December 19, 2023
 · 
6 min read
Deals
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
November 17, 2023
 · 
5 min read
BioMidwest
MAIA Biotechnology Announces $4 Million Registered Direct Offering
November 15, 2023
 · 
6 min read
FDA
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
November 10, 2023
 · 
8 min read
BioMidwest
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
November 7, 2023
 · 
9 min read
BioMidwest
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
October 30, 2023
 · 
6 min read
Drug Development
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
October 24, 2023
 · 
6 min read
BioMidwest
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023
October 19, 2023
 · 
6 min read
BioMidwest
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023
October 17, 2023
 · 
5 min read
BioMidwest
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
October 12, 2023
 · 
5 min read
Load More
JOBS